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Introduction
The treatment of acute promyelocytic leukemia (APL) has undergone remarkable improvements during the last two decades due to the introduction of all-trans-retinoic acid (ATRA) and arsenic, improved diagnostic tools and molecular monitoring, improved supportive care, and reduced doses of chemotherapy. 1, 2 Thanks to large cooperative studies, it has been possible to evaluate new treatment approaches in randomized trials despite the rareness of the disease. Most of our knowledge about APL is based on data from these large trials. However, clinical trials often exclude patients with high age, poor performance status (PS), abnormal hepatic or kidney function, or other comorbidities.
1,3-5 Sanz et al. 6 report that half of the patients excluded from the Spanish PETHEMA trials (LPA 96 and LPA 99) were excluded due to life-threatening hemorrhages. Patients may also die before any treatment has been initiated and even before diagnosis. 7 Thus, unselected APL populations probably have higher early death (ED) rates compared with clinical trials.
Despite the improvements in APL treatment, ED remains a problem with reported ED rates ranging between 7 and 14%. [3] [4] [5] [8] [9] [10] Recently, Jacomo et al. reported an ED rate of 32% in a study of APL patients at 12 Brazilian institutions receiving treatment with ATRA and anthracyclines. Hemorrhages, caused by disseminated intravascular coagulation, hypercoagulability, fibrinolysis, proteolysis and thrombocytopenia, constitute the major cause of death with the central nervous system (CNS) being the most common site of bleeding. 11, 12 Other causes of ED in APL are infections, multiorgan failure and the differentiation syndrome. 13, 14 In order to assess 'real world' data on ED as well as on other aspects of an unselected APL population, we analyzed patients diagnosed with APL and reported to the Swedish Acute Leukemia Registry, a nationwide population-based registry covering 98% of all acute leukemia cases in Sweden. 15 In addition, detailed information was achieved from patient records. We conclude that population-based data are important in order to assess true information on incidence and outcome in APL, and that the very high ED rate remains also in the western world.
Materials and methods

Patient data
All patients diagnosed with APL between 1997 and 2006 in the Swedish Adult Acute Leukemia Registry were included in the study. The registry contained 3897 adult acute patients over 16 years with acute leukemia, according to French-AmericanBritish criteria, not including teenage patients treated at pediatric departments. The Swedish Adult Acute Leukemia Registry is run in collaboration with the Regional Tumor Registry in all 6 Swedish healthcare regions, with a total population of 9 million, as previously reported. 15 The registry has 98% coverage of all acute leukemia patients against the Swedish Cancer Registry, which is a dual reporting system with compulsory reporting of all pathology specimens by pathologists and of newly diagnosed cancer patients by clinicians. In addition, a specific case-report form for every APL patient was sent out to their local hospital, and missing case-report forms were actively searched for; thus, additional information could be gathered in all but one case. The case-report form contained detailed information about the initial phase of the disease, including information regarding time between events, involved healthcare institutions, diagnostic procedures, type of antileukemic treatment and supportive care, and cause of death.
Definitions and diagnosis
Molecularly confirmed diagnosis was defined as a finding of t (15;17) in cytogenetic analysis, and/or positivity for PML-RARa in fluorescence in situ hybridization or reverse transcription-PCR analysis. High-risk patients were defined according to Sanz's risk score as previously described, 16 with white blood cells (WBC) 410 Â 10 9 /l; intermediate risk with WBC o10 Â 10 9 /l and platelet count o40 Â 10 9 /l; and low risk with WBC o10 Â 10 9 /l and platelet count 440 Â 10 9 /l. Morphologic diagnosis was made according to the French-American-British classification. 17 The immune phenotype of APL includes positivity for CD33, CD9, CD13 and CD117 and low expression of HLA-DR and CD34. ED was defined as death from any cause within 30 days from diagnosis.
Treatment
The treatment followed the national APL guidelines that underwent slight modifications during the study period (Table 1) . In addition to systemic treatment, patients o70 years with highrisk disease were given CNS prophylaxis with five intrathecal injections of 15 mg metothrexate, 50 mg Ara-C and methylprednisolone. During induction treatment, platelet counts were instructed to be kept above 30 Â 10 9 /l and transfusions should be given with a target platelet count of 50 Â 10 9 /l. Plasma was recommended to be given to patients with signs of coagulopathy, with a target fibrinogen blood value of 1.5 g/l. Treatment for differentiation syndrome (previously RAS) with intravenous dexamethasone was instructed to be given at the slightest suspicion of differentiation syndrome. Treatment with leukapheresis, low molecular heparin or inhibitors of fibrinolysis was not generally recommended.
Statistical analysis
For comparing continuous variables, such as blood chemistry, two-sided unpaired t-tests were used, and for categorical binominal variables w 2 -tests were used. Kaplan-Meier analysis with log-rank test was applied for survival analyses.
Results
Characterization of the study population
Of all the 3897 acute leukemia patients registered from 1997 to 2006, there were 3205 (82%) patients with non-APL acute myeloid leukemia (AML), 472 (12%) with acute lymphoblastic leukemia, 107 (2.7%) with undifferentiated/unclassified leukemia. There were 105 patients with APL, representing 2.7% of all acute leukemia cases and 3.2% of all AML cases.
The proportion of APL patients in the total AML population decreased with age from 17% in patients o30 years to 0.9% in patients 80 years and older (Supplementary Figure 1) . The APL incidence was 0.145 per 100 000 inhabitants per year, 0.179 in females and 0.113 in males. Sex-and age-dependent incidences are shown in Supplementary Figure 2 .
The mean age at the time of APL diagnosis was 52 years (range 18-86 years) and the median age 54 years. The corresponding figures for non-APL AML were 68 and 71 years, respectively. In all, 65 (62%) of the patients were women and 40 (38%) men. The proportion of females was considerably higher in the younger population. Thus, in APL patients aged less than 40 years, 89% were women. Abbreviations: ATRA, all-trans-retinoic acid; CR, complete remission.
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Diagnosis
The diagnostic procedures included immunophenotyping in 93% of patients below 70 years and in 87% in patients above 70 years. Cytogenetic analysis was performed in 93% of patients below 70 years and in 74% of patients aged 70 years or above. In all, 6 (6%) of the 105 APL patients lacked molecular diagnosis, defined as positivity for either t(15;17) in cytogenetic analysis or detection of PML-RARa by fluorescence in situ hybridization or reverse transcription-PCR. These patients were specifically reviewed for this study, and all six displayed typical morphologic and immunphenotypic features of APL as described above.
Performance status
Data on World Health Organization (WHO)/Eastern Cooperative Oncology Group PS at the time of diagnosis were available in 99 (94%) of the patients. Of patients below 60 years, 37% had PS 0 and 10% PS III/IV, whereas the corresponding figures for patients 60 years and older were 14 and 43%, respectively.
Early deaths
Of a total of 105 patients, 30 (29%) died within 30 days from diagnosis. The median time from the diagnostic bone marrow examination to death was 4 days (range 0-26). In all, 9 (30%) of the deaths occurred on the same day or the day after the diagnostic bone marrow examination, and 23 (77%) within the first week of diagnosis. Only two ED patients died more than 14 days from diagnosis ( Figure 1 ). Further through this study, ED is defined as death within 30 days from diagnosis, if not otherwise stated. Among men, the ED rate was 35% (14 of 40) and among women 25% (16 of 65) (P ¼ nonsignificant). The median and mean ages of the ED patients were 65 and 61 years as compared with 45 and 48 for non-ED patients, respectively (Po0.001). ED rates by age and WHO PS in APL compared with non-APL AML patients are shown in Table 2 . There were consistently higher ED rates according to age in APL as compared with non-APL AML (Table 2 , P ¼ 0.01). ED in relation to both WHO PS status and age as combined parameters is shown in Figure 2 .
Further characterization of patients
Further detailed patient information was gathered from review of medical records. Of the 105 patients, all but one could be further characterized in detail. Hemorrhage was the most common cause of death seen in 12 (41%) of the ED patients. Other causes of deaths are described in Table 3 . Hemorrhagic deaths were more common in younger patients, with fatal bleeding in 11 (53%) of the ED patients o70 years. The mean age of patients with hemorrhagic death vs non-hemorrhagic death was 52 vs 61 years (Po0.05), respectively. Hemorrhagic deaths occurred at a median of 4 days after diagnosis. Four patients died from CNS hemorrhage 47 days after start of treatment.
Of all ED patients, six (21%) received no antileukemic treatment (Supplementary Table 1 ). The main reason for receiving no treatment was very early deaths due to CNS hemorrhage. Table 4 shows the type of therapy given both to ED and non-ED patients, as well as other characteristics of the patient population. Of the four cases receiving chemotherapy without ATRA, two were initially misdiagnosed as non-APL AML. All non-ED patients received antileukemic treatment and only 3% did not receive ATRA.
The majority of ED patients first seeked help in a hospitalbased emergency ward, whereas most non-ED patients first attended a primary care unit. Half of the patients treated at nonuniversity hospitals suffered ED compared with 22% of patients treated at university hospitals (Po0.01)( Table 4 ). In patients below 70 years, ED rates were lower in both hospital types, but a difference in ED rate remained (30 vs 17%). Similar differences Continuing high early death rate in acute promyelocytic leukemia S Lehmann et al were seen also in younger age groups (data not shown). We also compared ED rates in regions with long distances between patients' domicile and treating hospitals (for example, the North region) as compared with regions with short distances (for example, the South region). Although there were some differences in ED rates between the six regions, these were not statistically significant, and the patient groups were too small to draw any conclusions (data not shown). The median number of days to start of ATRA treatment from the first health-care contact, the first contact with hematologist, and from the date of diagnosis was similar between the non-ED and the ED groups. The transfusion threshold for platelets (median limit 30 Â 10 9 /l, range 10-50) or the number of patients who received plasma or coagulation concentrates did also not differ between ED and non-ED patients. Several patients with early hemorrhagic death were not given plasma, despite low fibrinogen values, and the documented threshold for platelet transfusions were below 30 in 3 of these 12 patients. ED patients had significantly higher WBC, lactate dehydrogenase, creatinine and C-reactive protein, and lower platelets and albumin compared with non-ED patients (Supplementary Table 2 ). ED without hemorrhage was associated with C-reactive protein, 
Discussion
This study is, to our knowledge, the first truly population-based study of the incidence of APL with detailed characteristics of the patients. Its most important findings are the differences in sex and age distribution as compared with other APL studies and especially the continuing high early mortality rate, despite major improvements in the treatment.
The percentage of APL patients in this study was 2.7% of all acute leukemia patients and 3.2% of all AML patients, which is less compared with what has been reported previously. A main factor explaining the differences in the proportion of APL patients between different studies is the age of the study population. Our study showed a high proportion of APL in younger age groups as opposed to very low percentages in the higher age groups (Supplementary Figure 1) . Similar to acute lymphocytic leukemia in adults, the APL incidence is relatively constant through the age groups (Supplementary Figure 2) , contrasting to the sharp increase with higher age in non-APL AML. 15 Our incidence data are only slightly lower than in the SEER registry. 18 However, the median age at diagnosis of APL was considerably higher in our study as compared with other reports, 4,5,9 which might reflect that older patients have failed to enter these studies. Obviously, inclusion of older AML patients, as in this study, decreases the overall proportion of APL cases. This might be a part of the explanation to the suggested regional differences in APL incidence, with lower incidence in Northern Europe and Northern America, as compared with the higher incidence in Southern Europe and Latin America. [19] [20] [21] Interestingly, we also found surprising gender differences with a high proportion of women in APL patients below 40 years not previously reported. There is no obvious explanation for this female predominance, and with low number of patients, this needs to be confirmed in larger APL studies.
The most striking finding in this study is the high ED rate of 29% of the patients within the first 30 days from diagnosis. This is similar to what was reported from Brazil, 22 but considerably higher compared with recent European and North American clinical trials. 3, 4, [8] [9] [10] The main reason for the higher ED in the Swedish Registry compared with clinical trials is probably the inclusion of patients with very early deaths, as well as of patients who were not fit or too old for inclusion in clinical trials. Sanz et al. 6 report that half of the patients excluded from PETHEMA trials LPA 96 and LPA 99 were excluded due to life-threatening hemorrhages. As the Brazilian study included only patients who received ATRA in combination with anthrayclines, one could expect the population-based ED rate in Brazil to be even higher than the reported 32%. It should also be noted that the Brazilian study defined ED as a 14-day mortality. As there is no reason to believe that health-care resources or the management of APL patients is inferior in Sweden as compared with other developed Continuing high early death rate in acute promyelocytic leukemia S Lehmann et al countries, we suggest that the ED rates reported here are more close to what can be expected in an unselected APL population and also in many other Western countries. It is to note that the Swedish national guidelines during the study period included a platelet transfusion policy to keep platelets above 30 and administration of plasma or factor concentrates to keep fibrinogen 41.5 mg/l. ED in this study was defined as death within 30 days from diagnosis. Although some reports define ED as deaths within 10 or 14 days, 12, 22 other studies show that typical APL-dependent deaths, such as hemorrhagic deaths due to coagulopathy and death from differentiation syndrome, can occur during the third and fourth week after start of treatment. 11 Still, only two of the 30 deaths occurred more than 14 days after diagnosis, and the ED rate within day 14 was still as high as 27%. Several APL studies define ED as death during induction and before CR evaluation, including the period of aplasia following induction therapy. This definition should be relatively comparable to our 30-day definition. Similar to other reports, we show hemorrhagic death to be the major cause of death with almost all cases being CNS bleedings. The proportion of non-hemorrhagic deaths is slightly higher compared with most other studies, which is consistent with more older patients in this study.
ED was closely linked to age and poor PS, with 7.1% ED in patients with WHO PS I increasing to 78% ED in patients with WHO PS III and IV. Importantly, also patients aged 40-59 years had an ED rate of over 70% in the WHO PS III and IV groups. In patients above 60 years of age, the ED is strikingly high and it is in this patient group where our study population differs most compared with clinical trials. Patients above 60 years have poorer PS and more frequent and severe comorbidities, which probably are the main reasons for the high mortality in this age group.
Apart from high age and poor PS, several blood chemistry characteristics have been identified as risk factors for ED, including WBC, platelets, fibrinogen, creatinine, albumin and C-reactive protein. 11, 12, 23, 24 In our study, WBC, creatinine, C-reactive protein, lactate dehydrogenase, albumin and platelets were associated with ED, which is consistent with most other studies. Our study did not identify fibrinogen as associated to ED, neither in the total ED group nor in patients with hemorrhagic deaths. Some previous studies have identified fibrinogen as a risk factor, whereas others have not. 11, 12, 24 An important question is how many of the deaths that could have been prevented by better and more proactive initial management of the patients. Some very early deaths are realistically very difficult to prevent, and although only 13% of the deaths occurred before treatment was started, 30% of the deaths occurred on the day of diagnosis or the day after, making the time for preventive efforts very short. Still, a substantial number of deaths, including hemorrhagic deaths, occurred later during the first weeks of treatment, giving more time for preventive measures. It is not clear which proportion of the EDs in this study that could have been prevented by better adherence to guidelines, but some examples of non-compliance to the guidelines could be identified, such as lack of compliance to recommendations regarding platelet and plasma transfusions. Median times between first health-care contact, first contact with hematologist, diagnosis and start of treatment were short and similar between the non-ED and ED groups, but the spread was substantial and some delays in individual patients could be identified. However, the role of such delays for the death of individual cases is difficult to estimate. Patient's delay, as defined by time between the first symptoms to seeking medical care, was not evaluated in this study.
Patients treated in university hospitals showed lower ED rates compared with patients treated at smaller or intermediate-sized hospitals. Patients treated in university hospitals were somewhat younger; but also within the different age groups, the mortality was lower in university hospitals. It is still an unanswered question how many of these patients who could have been saved by urgent transportation from non-university hospitals to a specialized center. Some patients may have been too fragile to be moved from the local hospital. However, our data suggest that these complex patients should be treated in specialized units.
We conclude that population-based data are needed as a supplement to data from large randomized trials for information about the overall APL population. The most striking difference when studying population-based APL data is the higher ED rate, which reaches as high as approximately 30%. It is unclear how many of these deaths that are preventable, but we speculate that increased knowledge about the mechanisms of the coagulopathy, increased knowledge about APL in the medical community, earlier diagnosis and initiation of ATRA therapy on the mere suspicion of APL, better compliance to existing guidelines, centralization of the treatment to highly specialized hospitals, and new guidelines with more aggressive initial management of high-risk patients could decrease ED in APL. With the current treatment, patients who are saved from EDs have a high probability of cure.
